EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 435 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... November 15, 2022 Do Birth Control Pills Impact My Cancer Risk? October 20, 2022 Obesity May Help Tumors Survive and Grow, Mouse Study Suggests January 22, 2021 Cancer in My Community: Expanding Genetic Testing in Thailand October 11, 2022 Load more HOT NEWS Can the New “Omics” on the Block Find Liver Cancer in... Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line... Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness...
